Scarica l'app Stockscreener
2.87
5.28%
-0.16
Dopo l'orario di chiusura:
2.83
-0.04
-1.39%
Precedente Chiudi:
$3.03
Aprire:
$3.02
Volume 24 ore:
7.62M
Relative Volume:
1.71
Capitalizzazione di mercato:
$236.98M
Reddito:
-
Utile/perdita netta:
$-314.85M
Rapporto P/E:
-0.8011
EPS:
-3.5825
Flusso di cassa netto:
$-283.27M
1 W Prestazione:
+11.67%
1M Prestazione:
-65.87%
6M Prestazione:
-66.55%
1 anno Prestazione:
-71.33%
Intervallo 1D:
$2.52
$3.09
Intervallo di 1 settimana:
$2.335
$3.14
Portata 52W:
$1.50
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
2.87 | 250.20M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Downgrade | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Downgrade | Jefferies | Buy → Hold |
| 2026-04-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-04-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
FDA head Makary defends drug application rejections amid criticism - Seeking Alpha
REPL Stock Plunges As FDA Rejects Key Melanoma Therapy - StocksToTrade
What's Going On With Replimune Stock On Tuesday? - Benzinga
REPL Nosedives As FDA Chief Stands Firm Against Melanoma Treatment: ‘I Don’t Work For Replimune…’ - Stocktwits
REPL Stock Plunges As FDA Rejection Triggers Legal And Wall Street Backlash - timothysykes.com
FDA Commissioner Makary defends agency's decision on Replimune's drug, CNBC reports - Reuters
FDA Commissioner Makary defends agency's decision on Replimune's drug - marketscreener.com
Fda's Makary on Replimune's Drug Says If the Clinical Trials Show That It Works, It's Going to Get ApprovedCnbc - marketscreener.com
Fda's Makary on Replimune Says Three Indepndent Teams Arrived at the Same ConclusionsCnbc - marketscreener.com
Fda's Makary Defends Agency's Decision On Replimune's Cancer Drug -Cnbc - marketscreener.com
Replimune plunges after FDA rejects skin cancer drug again - MSN
REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN
FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients - The Cancer Letter
Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8% - MarketBeat
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - PR Newswire
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, In - The National Law Review
Replimune Group (REPL) price target decreased by 59.94% to 5.04 - MSN
Street sours on Replimune as stock hits all-time low on melanoma drug rejection - MSN
MSN Money - MSN
MSN - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Shareholders to Connect - ACCESS Newswire
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - FinancialContent
Opinion | Replimune’s Fate Is Worse Than a Tragedy - WSJ
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Replimune under pressure as FDA rejects lead asset again - MSN
2026-04-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out | NDAQ:REPL | Press Release - Stockhouse
Replimune brings 3-year melanoma survival data to ASCO oral session - Stock Titan
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
200+ Mass. biotech employees were laid off last week. That may only be the beginning - MSN
Wedbush Upgrades Replimune Group (REPL) - MSN
Replimune plans layoffs as FDA rejects cancer drug - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
REPL Stock Crashes As FDA Rejects RP1 Melanoma Bid Again - StocksToTrade
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid - StocksToTrade
REPL Stock Collapses As FDA Rejection Triggers Downgrades - StocksToTrade
JP Morgan Downgrades Replimune Group (REPL) - MSN
Replimune Group Stock Short Interest Rises to 43.93% - Quiver Quantitative
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):